Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Apr 09, 2021 1:02pm
116 Views
Post# 32967364

RE:RE:Remember that time

RE:RE:Remember that time
frewil11 wrote: Tripp should be held accountable , its always everybodies else fault except Tripp.



Painful to see this beaten down day after day. Standing back and looking at this objectively would tell any reasonable person that the sp is far too low. Buyers should be clamouring to get in at this price.  We are mentioned in the same sentence as Grail (even Tripp), as a competitor, yet we have basically what Grail is trying to perfect - and there is a court challenge there as well which we don' t have.  All of this, despite a bungled rollout, should be enough to create the knd of interest we need.  My hope is that we receive some favourable independent press on Aristotle's release which generates interest and gets us on the investment map. 
<< Previous
Bullboard Posts
Next >>